Compare SKYT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | AMLX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2021 |
| Metric | SKYT | AMLX |
|---|---|---|
| Price | $33.38 | $18.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $26.50 | $21.56 |
| AVG Volume (30 Days) | 734.2K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $442,139,000.00 | $380,786,000.00 |
| Revenue This Year | $40.16 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 29.18 | ★ 1612.94 |
| 52 Week Low | $8.49 | $7.48 |
| 52 Week High | $39.93 | $19.15 |
| Indicator | SKYT | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 68.11 |
| Support Level | $26.99 | $12.17 |
| Resistance Level | $34.40 | $18.61 |
| Average True Range (ATR) | 1.52 | 1.01 |
| MACD | -0.36 | 0.21 |
| Stochastic Oscillator | 10.34 | 80.18 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play semiconductor foundry providing foundational-node manufacturing, advanced technology development, and advanced packaging services through an integrated, multi-site operating model. It operates within the United States, with fabrication and packaging facilities in Minnesota, Texas, and Florida.l. Its segments include: Legacy SkyWater: A pure-play technology foundry that offers advanced semiconductor development and manufacturing services from its fabrication facility in Bloomington, Minnesota and advanced packaging services from its Kissimmee Florida facility; and SkyWater Texas: A high-volume manufacturer that offers manufacturing services from its fabrication facility in Austin, Texas.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.